C.M. Bidwell & Associates’s Bioventus BVS Stock Holding History

C.M. Bidwell & Associates’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,525	Closed	-$44K	–	565
2021 Q2	$44K	Buy	+2,525	New	+$40.7K	0.03%	313

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuance Investments Kansas City, Missouri $717M AUM 3.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JIC

Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

C.M. Bidwell & Associates's BVS Position: Q3 2021 in Review

C.M. Bidwell & Associates sold out of Bioventus (BVS) in Q3 2021, closing a stake of 2,525 shares — an estimated $44K sold.

C.M. Bidwell & Associates first reported a position in BVS in Q2 2021 and held it in 1 quarter. The position peaked at $44K in Q2 2021. 69 funds tracked by Wall St. Rank hold BVS as of Q3 2021.

C.M. Bidwell & Associates reported no remaining Bioventus position as of Q3 2021 after selling out during the quarter.
C.M. Bidwell & Associates sold 2,525 Bioventus shares in Q3 2021, an estimated $44K.
C.M. Bidwell & Associates first reported a position in Bioventus in Q2 2021 and held it in 1 quarter.
C.M. Bidwell & Associates's Bioventus position peaked at $44K in Q2 2021.
69 funds tracked by Wall St. Rank held Bioventus as of Q3 2021.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2021, filed 12 Nov 2021.